University of Alabama at Birmingham at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Alabama at Birmingham brings 3 presentations to ASH 2026 in New Orleans. Its program ranges from sickle cell trial design and iron deficiency to protein-degrader drugs for myeloma. It also compares oral and intravenous iron in menstruating and pregnant patients, and covers education resources for hematology trainees worldwide.
| Organization | ASH 2026 Attendance |
|---|---|
University of Alabama at Birmingham Birmingham, AL | |
Public research university and academic medical center in Birmingham, Alabama. | Symposium Fri Dec 11 11:00am–2:00pm Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera Newer options for polycythemia vera and essential thrombocythemia, such as ropeginterferon and rusfertide, and what to do when hydroxyurea fails. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. Talk Showcasing ASH Resources for Continuing Medical Education for Local and International Trainees and Practitioners Digital learning, clinical guidelines, and visiting-trainee mentorship programs that expand hematology training worldwide and build lasting local expertise. Talk After the Fall: Trial Design, National and International, in the Modern Era of Sickle Cell Disease Why sickle cell disease trials have struggled, and how more objective endpoints could let more patients enroll and speed new therapies. |
Instantly find 20 buyers from University of Alabama at Birmingham
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction